Neurogene Inc :* NEUROGENE INC - MODIFIE L'ACCORD AVEC BAKER BROS POUR AUGMENTER LE SEUIL DE NOMINATION - DÉPÔT AUPRÈS DE LA ...

Investing.com — Neurogene Inc. (NASDAQ: NGNE ), une entreprise pharmaceutique avec une capitalisation boursière de 163,48 millions $, a annoncé aujourd’hui une modification à un accord existant avec B ...

BMO Capital analyst Keith Tapper lowered the firm’s price target on Neurogene (NGNE) to $16 from $45 and keeps an Outperform rating on the ...

Investing.com — Lundi, BMO Capital Markets a ajusté ses perspectives sur Neurogene (NASDAQ: NGNE) en réduisant considérablement l’objectif de cours de la société de 45,00$ à 16,00$. Malgré ce changeme ...

Neurogene Inc.’s NGNE share price has dipped by 11.19%, which has investors questioning if this is right time to buy.

Wall Street on Friday suffered its biggest weekly retreat since the peak of the COVID-19 pandemic collapse in 2020. The panic ...

Scientists have developed a new transgene control system that shows early promise for treating rare brain disorder Rett syndrome.

NEW YORK - Neurogene Inc. (NASDAQ: NGNE), a clinical-stage biotech company currently valued at $156 million, has announced the publication of a study in Science Translational Medicine detailing its ...

Alkermes plc announced today that management will participate in a webcast panel discussion "Development of Orexin Receptor Agonist in Sleep-Wake Disorders" at the upcoming 24th Annual Needham Virtual ...

Neurogene (NGNE) announced a peer-reviewed publication on its EXACT transgene regulation technology. The preclinical ...

At OFC 2025, Luxshare-Tech, a leader in high-performance interconnect solutions, and Semtech, a leading provider of high-performance semiconductors, Internet of Things (IoT) systems and cloud ...